Bank Of America Crosses Below Threshold Of 10% Of Lakefront's Voting Rights, Transparency Notification Shows

Lakefront kondigt de verkoop aan van haar preklinische CAR-T-programma’s aan Armed Cell Therapeutics

Lakefront Biotherapeutics has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV for an €8 million upfront payment plus up to $230 million in milestone payments and royalties. The transaction marks the near-completion of Lakefront's previously announced wind-down of cell therapy activities, allowing the company to focus on its T-cell engager pipeline while providing shareholders potential upside from Armed Cell's future progress.

Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics

Lakefront Biotherapeutics has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics for €8 million upfront plus up to $230 million in milestone payments and royalties. The sale marks the substantial completion of Lakefront's previously announced wind-down of legacy cell therapy activities, allowing the company to focus on its newly established T-cell engager pipeline while shareholders retain potential upside from future progress.

Lakefront Biotherapeutics Completes Sale Of Early-Stage Cell Therapy Pipeline To Armed Cell Therapeutics For €8M Upfront, Up To $230M In Milestones